Advertisements
Feeds:
Posts
Comments

Archive for the ‘Artificial Intelligence Applications in Health Care’ Category

Digital Therapeutics: A threat or opportunity to pharmaceuticals


Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Digital Therapeutics (DTx) have been defined by the Digital Therapeutics Alliance (DTA) as “delivering evidence based therapeutic interventions to patients, that are driven by software to prevent, manage or treat a medical disorder or disease”. They might come in the form of a smart phone or computer tablet app, or some form of a cloud-based service connected to a wearable device. DTx tend to fall into three groups. Firstly, developers and mental health researchers have built digital solutions which typically provide a form of software delivered Cognitive-Behaviour Therapies (CBT) that help patients change behaviours and develop coping strategies around their condition. Secondly there are the group of Digital Therapeutics which target lifestyle issues, such as diet, exercise and stress, that are associated with chronic conditions, and work by offering personalized support for goal setting and target achievement. Lastly, DTx can be designed to work in combination with existing medication or treatments, helping patients manage their therapies and focus on ensuring the therapy delivers the best outcomes possible.

 

Pharmaceutical companies are clearly trying to understand what DTx will mean for them. They want to analyze whether it will be a threat or opportunity to their business. For a long time, they have been providing additional support services to patients who take relatively expensive drugs for chronic conditions. A nurse-led service might provide visits and telephone support to diabetics for example who self-inject insulin therapies. But DTx will help broaden the scope of support services because they can be delivered cost-effectively, and importantly have the ability to capture real-world evidence on patient outcomes. They will no-longer be reserved for the most expensive drugs or therapies but could apply to a whole range of common treatments to boost their efficacy. Faced with the arrival of Digital Therapeutics either replacing drugs, or playing an important role alongside therapies, pharmaceutical firms have three options. They can either ignore DTx and focus on developing drug therapies as they have done; they can partner with a growing number of DTx companies to develop software and services complimenting their drugs; or they can start to build their own Digital Therapeutics to work with their products.

 

Digital Therapeutics will have knock-on effects in health industries, which may be as great as the introduction of therapeutic apps and services themselves. Together with connected health monitoring devices, DTx will offer a near constant stream of data about an individuals’ behavior, real world context around factors affecting their treatment in their everyday lives and emotional and physiological data such as blood pressure and blood sugar levels. Analysis of the resulting data will help create support services tailored to each patient. But who stores and analyses this data is an important question. Strong data governance will be paramount to maintaining trust, and the highly regulated pharmaceutical industry may not be best-placed to handle individual patient data. Meanwhile, the health sector (payers and healthcare providers) is becoming more focused on patient outcomes, and payment for value not volume. The future will say whether pharmaceutical firms enhance the effectiveness of drugs with DTx, or in some cases replace drugs with DTx.

 

Digital Therapeutics have the potential to change what the pharmaceutical industry sells: rather than a drug it will sell a package of drugs and digital services. But they will also alter who the industry sells to. Pharmaceutical firms have traditionally marketed drugs to doctors, pharmacists and other health professionals, based on the efficacy of a specific product. Soon it could be paid on the outcome of a bundle of digital therapies, medicines and services with a closer connection to both providers and patients. Apart from a notable few, most pharmaceutical firms have taken a cautious approach towards Digital Therapeutics. Now, it is to be observed that how the pharmaceutical companies use DTx to their benefit as well as for the benefit of the general population.

 

References:

 

https://eloqua.eyeforpharma.com/LP=23674?utm_campaign=EFP%2007MAR19%20EFP%20Database&utm_medium=email&utm_source=Eloqua&elqTrackId=73e21ae550de49ccabbf65fce72faea0&elq=818d76a54d894491b031fa8d1cc8d05c&elqaid=43259&elqat=1&elqCampaignId=24564

 

https://www.s3connectedhealth.com/resources/white-papers/digital-therapeutics-pharmas-threat-or-opportunity/

 

http://www.pharmatimes.com/web_exclusives/digital_therapeutics_will_transform_pharma_and_healthcare_industries_in_2019._heres_how._1273671

 

https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/exploring-the-potential-of-digital-therapeutics

 

https://player.fm/series/digital-health-today-2404448/s9-081-scaling-digital-therapeutics-the-opportunities-and-challenges

 

Advertisements

Read Full Post »


  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON

https://worldmedicalinnovation.org/agenda/

Aviva Lev-Ari, PhD, RN Founder, LPBI Group

will cover this event in Real Time

@AVIVA1950

@pharma_BI

 

 

Monday, April 8, 2019

7:00 am – 8:00 am
7:00 am – 5:00 pm
8:00 am – 9:40 am
Bayer Ballroom

First Look

Nine rapid fire presentations on the applications of AI in Clinical Care

Moderator: Giles Boland, MD
  • Chair, Department of Radiology, BWH; Philip H. Cook Professor of Radiology, HMS
Moderator: Trung Do
  • VP, Business Development, Innovation, PHS
9:40 am – 9:55 am
9:55 am – 11:35 am
Bayer Ballroom

First Look

Nine rapid fire presentations on the applications of AI in Clinical Care

11:45 am – 1:00 pm

Discovery Café Sessions

Lunch with Top Leading Experts: Intensive sessions addressing cutting-edge artificial intelligence topics.

Applying AI to Save Lives During the Opioid Crisis

The U.S. is in the throes of a devastating epidemic of opioid addiction and overdose — some 130 people die in this country every day from opioids, says the National Institute on Drug Abuse. With a total economic cost of more than $78 billion a year, academic and industry organizations are harnessing AI to develop new tools that can help alleviate this national crisis. This session will discuss some of the AI-based strategies that academic and industry teams are leveraging to help clinical and public health officials better predict, identify, and treat opioid addiction, as well as some of the concerns around data privacy.

Moderator: Thomas Sequist, MD, Chief Quality & Safety Officer, PHS

Bob Burgin, CEO, Amplifire Healthcare Alliance

Carm Huntress, CEO, RxRevu Inc

Sarah Wakeman, MD, Medical Director, Substance Use Disorder Initiative, MGH; Assistant Professor, Medicine, HMS

Scott Weiner, MD, Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program, BWH; Assistant Professor, HMS

 

Community Hospitals: Key Component in Healthcare Transformation

Community hospitals are the largest sources of patient care in the U.S. As such, they represent a critical frontier in the transformation of health care. How are these organizations using AI and digital technologies to drive transformation? What are the key distinctions from academic medical centers? This session will address these and other critical topics that impact community hospitals and their essential, though often overlooked, role in health care.

Moderator: Michael Jaff, DO, President, NWH, PHS, Professor of Medicine, HMS

Fabien Beckers, PhD, CEO, Arterys

Joanna Geisinger, CEO, TORq Interface

Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Professor, Neurology, HMS

Tal Wenderow, CEO, Beyond Verbal

 

Digital Management of Diabetes

Across the full spectrum of patient care, the management of diabetes has been flooded with new technology and treatment options for both type 1 and type 2 diabetes – there is a range of new devices and software, including automatic insulin infusion systems, glucose sensors, AI-based algorithms and decision support tools, with artificial pancreas on the horizon. This session will focus on these areas as well as clinical use cases that highlight the value of AI.

Moderator: Deborah Wexler, MD, Clinical Director, Diabetes Center, MGH; Associate Professor, HMS

Marie McDonnell, MD, Section Chief and Director, Diabetes Program, BWH; Lecturer, HMS

Joshua Riff, MD, CEO, Onduo

 

Emergency Medicine

 

Mental Health and the Promise of AI

Moderator: Sabine Wilhelm, PhD, Chief of Psychology; Director, OCD and Related Disorders Program, MGH; Professor, Psychology, HMS

Thomas McCoy, MD, Director of Research, Center for Quantitative Health, MGH; Assistant Professor, Psychiatry & Medicine, HMS

Christopher Molaro, CEO, Neuroflow

David Silbersweig, MD, Chairman, Department of Psychiatry, BWH; Stanley Cobb Professor of Psychiatry, HMS

 

From Startup to Impact (Pharma and Diagnostics)

With all the hype surrounding AI, this session will focus on what really matters. Impact! Who is really moving the needle in life sciences today? This session will introduce you to five leading companies who will share their client stories over lunch.

Moderator: James Brink, MD, Radiologist-in-Chief, MGH; Juan M. Taveras Professor of Radiology, HMS

1:00 pm – 1:15 pm
1:15 pm – 1:45 pm
Bayer Ballroom
1:45 pm – 2:35 pm
Bayer Ballroom

AMC AI Strategy: AI from the Top

  • Board Member, PHS; President Emerita and Professor of Neuroscience, MIT
  • Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2019 Forum Co-Chair
  • Chief Clinical Officer, PHS; Professor of Medicine, HMS; 2019 Forum Co-Chair
2:35 pm – 3:25 pm
Bayer Ballroom

RWE and Trial Optimization in the AI Era

Moderator: Thomas Lynch, MD
  • EVP and CSO, R&D, Bristol-Myers Squibb
  • CMO, CSO, SVP Oncology, Flatiron Health
  • EVP MA&PV and Bayer CMO, Bayer AG
  • Chief Architect, Microsoft Healthcare
  • CEO, My Own Med Inc.
  • Executive Director, Clinical Trials Office, PHS; Associate Professor of Medicine, HMS
3:25 pm – 4:15 pm
Bayer Ballroom

AI Driven Value-Based Care

Moderator: Timothy Ferris, MD
  • CEO, MGPO; Professor of Medicine, HMS
  • CEO, American Heart Association
  • EVP, President, Network Solutions Change Healthcare
  • Vice Chairman, Investment Banking and Managing Director Lazard Freres
  • CEO, NHS England
4:15 pm – 5:05 pm
Bayer Ballroom

Cardiovascular Care: Reinvented Through AI

  • Vice Chair for Scientific Innovation, Department of Medicine, BWH; Associate Professor of Medicine, HMS
  • President, Bayer Pharma Americas Region, Bayer
  • Director, Cardiac Imaging MR PET CT Program, MGH; Professor, Medicine, HMS
5:15 pm – 6:15 pm

Tuesday, April 9, 2019

7:00 am – 8:00 am
7:00 am – 5:00 pm
7:50 am – 8:00 am
Bayer Ballroom

Opening Remarks

  • Chief Innovation Officer, PHS; President, Partners HealthCare International
8:00 am – 8:50 am
Bayer Ballroom

Implementing AI in Cancer Care

  • Associate Surgeon, BWH; Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology, HMS
  • Chief, Breast Imaging Division, MGH; Professor of Radiology, HMS
  • President and Co-Founder, LunaDNA
  • Delta Electronics Professor, Electrical Engineering and Computer Science Department, MIT
  • Director, Cancer Genome Analysis, Broad Institute; Professor of Pathology, HMS
  • CEO, insitro
8:50 am – 9:40 am
Bayer Ballroom

Imagining Medicine in the Year 2054

In 1984 Isaac Asimov was asked to predict what life in 2019 would be like. Using the same aperture, we as what will health care look like 35 years from now? What capabilities will clinicians have that they now struggle with? And what will be the biggest challenges? Current trends suggest that we will see some significant gains in the areas of cancer immunotherapy, gene therapy for devastating rare diseases, and treatments for common neuropsychiatric conditions, including schizophrenia and depression. Panelists will draw on their visionary perspective and will reflect on what to expect and why.

Moderator: Keith Flaherty, MD
  • Director, Clinical Research, MGH; Professor of Medicine, HMS
  • Vice Chair for Scientific Innovation, Department of Medicine, BWH; Associate Professor of Medicine, HMS
  • Director, Cellular Immunotherapy Program, MGH; Assistant Professor, Medicine, HMS
  • Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
  • CEO, Biogen
9:40 am – 10:10 am
10:10 am – 10:40 am
Bayer Ballroom
10:40 am – 11:30 am
Bayer Ballroom

CEO Roundtable

Moderator: Anne Klibanski, MD
  • Chief Academic Officer, PHS; Laurie Carrol Guthart Professor of Medicine, Academic Dean for Partners, HMS; 2019 Forum Co-Chair
  • EVP and Chief Commercial Officer, Bristol-Myers Squibb
  • CEO, Philips
  • EVP, Head, Pharmaceuticals Research & Development, Bayer AG
  • CEO, Siemens Healthineers
  • CEO, GE Healthcare
11:45 am – 1:00 pm

Discovery Cafe Sessions

Lunch with Top Leading Experts: Intensive sessions addressing cutting-edge artificial intelligence topics.

Back Office of the Provider Future

Moderator: Peter Markell, EVP, Administration and Finance, CFO and Treasurer, PHS

Kent Ivanoff, CEO, VisitPay

Connie Moser, Chief Operating Officer, Verge Health

 

Chief Digital Strategy Officer Roundtable

With the advent of healthcare AI-enabled technologies, this session brings together several chief digital health officers from a range of organizations. The discussion will address key tradeoffs in sequencing technology across academic medical centers; what technologies are being prioritized; and how consumer expectations are impacting the future delivery model of healthcare.

Moderator: Alistair Erskine, MD, Chief Digital Health Officer, PHS

Michael Anderes, Chief Innovation and Digital Health Officer, Froedtert Health; President, Inception Health

Adam Landman, MD, VP and CIO, Brigham Health; Associate Professor of Emergency Medicine, HMS

Aimee Quirk, CEO, innovationOchsner

Richard Zane, MD, Chief Innovation Officer, UCHealth; Professor and Chair,Department of Emergency Medicine, University of Colorado School of Medicine

 

Innovation Fellows: A New Model of Collaboration

The Innovation Fellows Program provides short-term, experiential career development opportunities for future leaders in health care focused on accelerating collaborative innovation between science and industry. It facilitates personnel exchanges between Harvard Medical School staff from Partners’ hospitals and participating biopharmaceutical, device, venture capital, digital health, payor and consulting firms. A successful example of open innovation, Fellows and Hosts learn from each other as they collaborate on projects ranging from clinical development to digital health & artificial intelligence to new care delivery models and industry disruption. Come listen to the experience and insights of our panelists, including Fellows, Industry Partners and hospital leadership, and learn how this new model of collaboration can deliver value and lead to broader relationships between industry and academia.

 

Last Mile: Fully Implementing AI in Healthcare

Moderator: Keith Dreyer, DO, PhD, Chief Data Science Officer, PHS; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS

Katherine Andriole, PhD, Director of Research Strategy and Operations, MGH & BWH CCDS; Associate Professor, Radiology, HMS

Samuel Aronson, Executive Director, IT, Personalized Medicine, PHS

Seth Hain, VP of R&D, Epic

Jonathan Teich, MD, PhD, Chief Medical Information Officer, InterSystems; Emergency Medicine, BWH

 

Reimagining Disease Management

Moderator: Sree Chaguturu, MD, Chief Population Health Officer, PHS; Assistant Professor, Medicine, HMS

Murray Brozinsky, Chief Strategy Officer, Conversa

Jean Drouin, MD, CEO, Clarify Health Solutions

Sandhya Rao, MD, Senior Medical Director, Population Health, PHS; Assistant Professor, Medicine, HMS

 

Standards and Regulation: The Emerging AI Framework

 

From Startup to Impact (Provider Solutions)

With all the hype surrounding AI, this session will focus on what really matters. Impact! Who is really moving the needle for healthcare providers today? This session will introduce you to five leading companies who will share their client stories over lunch.

Moderator: Meredith Fisher, PhD, Partner, Partners Innovation Fund, PHS

 

1:00 pm – 1:10 pm
1:10 pm – 2:00 pm
Bayer Ballroom

China: AI Enabled Healthcare Leadership

Moderator: James Bradner, MD
  • President, Novartis Institutes for Biomedical Research
  • CEO, Infervision
  • Managing Partner, Qiming Venture Partners
2:00 pm – 2:30 pm
Bayer Ballroom

1:1 Fireside Chat: Mark Benjamin, CEO, Nuance

Moderator: Peter Slavin, MD
  • President, MGH; Professor, Health Care Policy, HMS
  • CEO, Nuance Communications
2:30 pm – 3:00 pm
3:00 pm – 3:50 pm
Bayer Ballroom

Getting to the AI Investment Decision

  • VP, Venture & Managing Partner, Partners Innovation Fund, PHS
  • Managing Director, Bain Capital Life Sciences
  • Managing Partner, Polaris Partners
  • SVP, Strategy, Commercialization & Innovation, Amgen
  • Managing Director, Healthcare Group, Goldman Sachs
  • Partner, Google Ventures
3:50 pm – 4:20 pm
Bayer Ballroom
4:20 pm – 5:10 pm
Bayer Ballroom

Consumer Healthcare and New Models of Care Delivery

Moderator: Diana Nole
  • CEO, Wolters Kluwer Health
  • President, Global Strategy Group, Samsung; Founder, CareVisor
  • VP and Global CTO, Sales, Dell EMC
  • President, Health Platforms, Verily Life Sciences
  • VP and Chief Health Officer, IBM Corporation
  • SVP, Head of Innovation and Health Equity Microsoft Healthcare
5:15 pm – 6:15 pm

Wednesday, April 10, 2019

7:00 am – 12:00 pm
7:30 am – 9:30 am
Bayer Ballroom

Innovation Discovery Grant Awardee Presentations

Twelve clinical AI teams culled through the Innovation Discovery Grant program present their work illustrating how AI can be used to improve patient health and healthcare delivery. This session is designed for investors, entrepreneurs, investigators, and others who are interested in commercializing AI opportunities that are currently in development with support from the Innovation Office.

Moderator: David Louis, MD
  • Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, HMS
9:30 am – 10:00 am
10:00 am – 10:30 am
Bayer Ballroom

1:1 Fireside Chat: Stefan Oelrich, Member of the Board of Management; President, Pharmaceutical, Bayer AG

Moderator: Betsy Nabel, MD
  • President, Brigham Health; Professor of Medicine, HMS
  • Member of the Board of Management, Bayer AG; President, Pharmaceutical, Bayer AG
10:30 am – 11:00 am
Bayer Ballroom

1:1 Fireside Chat: Deepak Chopra, MD, Founder, The Chopra Foundation

Moderator: Rudolph Tanzi, PhD
  • Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
  • Founder, The Chopra Foundation
11:00 am – 11:50 am
Bayer Ballroom

Using AI to Predict and Monitor Human Performance and Neurological Disease

  • Chief of Neurology, Co-Director, Neurological Clinical Research Institute, MGH; Julieanne Dorn Professor of Neurology, HMS
  • Chief Scientist, Dolby Laboratories
  • Global Therapeutic Head, Neuroscience Janssen Research & Development
  • EVP and CMO, Biogen
  • CEO, Kitman Labs
11:50 am – 12:50 pm
Bayer Ballroom

Disruptive Dozen: 12 Technologies that will reinvent AI in the Next 12 Months

The culture of innovation throughout Partners HealthCare naturally fosters robust discussions about new “disruptive” technologies and which ones will have the biggest impact on health care. The Disruptive Dozen was created to identify and rank the technologies that Partners faculty feel will break through over the next decade to significantly improve health care. This year, the Disruptive Dozen focuses on relevant advances and opportunities in artificial intelligence (AI).

Moderator: Jeffrey Golden, MD
  • Chair, Department of Pathology, BWH; Ramzi S. Cotran Professor of Pathology, HMS
  • Associate Chief, Infection Control Unit, MGH; Assistant Professor, Medicine, HMS
1:00 pm – 1:10 pm
Bayer Ballroom

Read Full Post »


Artificial intelligence can be a useful tool to predict Alzheimer

Reporter: Irina Robu, PhD

The Alzheimer’s Association estimate that around 5.7 million people live with Alzheimer’s disease in the United States which will rise to almost 14 million by 2050. Earlier diagnosis would not only benefit those affected, but it could also jointly save about $7.9 trillion in medical care and related costs over time. As Alzheimer’s disease progresses, it changes how brain cells use glucose. This alteration in glucose metabolism shows up in a type of PET imaging that tracks the uptake of a radioactive form of glucose called 18F-fluorodeoxyglucose. By giving instructions about what to look for, the scientists were able to train the deep learning algorithm to assess the PET images for early signs of Alzheimer’s.
The researchers from University of California San Francisco used positron-emission tomography images of 1002 people’s brain to train the deep learning algorithm they developed. They used 90 percent of images to teach the algorithm to spot features of Alzheimer’s disease and the remaining 10 percent to verify its performance. The researchers tested the algorithm on PET images of brains from 40 people, from which they were able to predict which individuals would receive a final diagnosis of Alzheimer’s. On average, the people who were tested were diagnosed with the disease more than 6 years after the scans.
According to the Radiology journal in which the research was published, the team describes how the algorithm “achieved 82 percent specificity at 100 percent sensitivity, an average of 75.8 months prior to the final diagnosis.” The researchers taught the algorithm with the help of more than 2,109 PET images of 1,002 individuals’ brains. The algorithm uses deep learning, which allows the algorithm to “teach itself” what to look for by spotting subtle differences among the thousands of images. The algorithm was as good as, if not better than, human experts at analyzing the FDG PET images.
Future advances will involve using larger data sets and additional images taken over time from people at various clinics and institutions. In the future, the algorithm could be a beneficial addition to the radiologist’s toolbox and advance opportunities for the early treatment of Alzheimer’s disease.

Source

https://www.medicalnewstoday.com/articles/323608.php

 

Read Full Post »


Artificial Intelligence in Health Care and in Medicine: Diagnosis & Therapeutics

Reporter: Aviva Lev-Ari, PhD, RN

 

News You Need to Know Today

Monday, January 21, 2019

Top Stories

Mayo Clinic researchers use AI, EKG test to detect heart condition

AI applied to an electrocardiogram (EKG) test reliably detected asymptomatic left ventricular dysfunction (ALVD)—a precursor to heart failure—and predicted which patients were most at risk of developing the condition in the future, according to a Mayo Clinic study.

Radiologists at Belgian hospital adopt Aidoc neuro tool into workflows

The radiology department at the Antwerp University Hospital in Belgium has incorporated an Aidoc tool that uses AI to help radiologists make faster diagnoses from CT scans, the university announced Wednesday, Jan. 16.

AI algorithm outperforms doctors at finding cervical cancer

AI may be better at spotting cervical cancer and precancer after a study found a deep-learning algorithm was more accurate at recognizing the disease than human doctors.

Machine learning detects, treats UTIs earlier

Scientists at the University of Surrey in Guildford, England, developed a tool that uses machine learning to identify and treat urinary tract infections at early stages in dementia patients, according to a study published in PLOS One.

Featured Articles

GE Healthcare, Vanderbilt to develop AI-powered apps for immunotherapy cancer treatments

GE Healthcare and the Vanderbilt University Medical Center (VUMC) have partnered to develop diagnostic tools and AI-powered applications to create safer and more precise immunotherapy treatments for cancer patients.

AI-powered app can screen for anemia with fingernail picture

An Atlanta research team has developed a smartphone app that can screen for anemia just by taking a picture of a person’s fingernails—paving the way for a new, noninvasive method to detect and diagnose the condition.

UPCOMING

[Video Presentation] Architecting AI: Rethinking Medical Imaging & Defining the Strategy

Jan 30, 2019 | 2PM ET We asked the questions you want to: Why is imaging ripe for AI? How will improvements in image processing and reconstruction, quality control and work list prioritization improve the practice of radiology? Register today.

SOURCE

From: AI in Healthcare <news@mail.clinical-innovation.com>

Reply-To: AI in Healthcare <news@mail.clinical-innovation.com>

Date: Monday, January 21, 2019 at 7:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Diagnostics | January 2019

Read Full Post »


Role of Informatics in Precision Medicine: Notes from Boston Healthcare Webinar: Can It Drive the Next Cost Efficiencies in Oncology Care?

Reporter: Stephen J. Williams, Ph.D.

 

Boston Healthcare sponsored a Webinar recently entitled ” Role of Informatics in Precision Medicine: Implications for Innovators”.  The webinar focused on the different informatic needs along the Oncology Care value chain from drug discovery through clinicians, C-suite executives and payers. The presentation, by Joseph Ferrara and Mark Girardi, discussed the specific informatics needs and deficiencies experienced by all players in oncology care and how innovators in this space could create value. The final part of the webinar discussed artificial intelligence and the role in cancer informatics.

 

Below is the mp4 video and audio for this webinar.  Notes on each of the slides with a few representative slides are also given below:

Please click below for the mp4 of the webinar:

 

 


  • worldwide oncology related care to increase by 40% in 2020
  • big movement to participatory care: moving decision making to the patient. Need for information
  • cost components focused on clinical action
  • use informatics before clinical stage might add value to cost chain

 

 

 

 

Key unmet needs from perspectives of different players in oncology care where informatics may help in decision making

 

 

 

  1.   Needs of Clinicians

– informatic needs for clinical enrollment

– informatic needs for obtaining drug access/newer therapies

2.  Needs of C-suite/health system executives

– informatic needs to help focus of quality of care

– informatic needs to determine health outcomes/metrics

3.  Needs of Payers

– informatic needs to determine quality metrics and managing costs

– informatics needs to form guidelines

– informatics needs to determine if biomarkers are used consistently and properly

– population level data analytics

 

 

 

 

 

 

 

 

 

 

 

 

What are the kind of value innovations that tech entrepreneurs need to create in this space? Two areas/problems need to be solved.

  • innovations in data depth and breadth
  • need to aggregate information to inform intervention

Different players in value chains have different data needs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Data Depth: Cumulative Understanding of disease

Data Depth: Cumulative number of oncology transactions

  • technology innovators rely on LEGACY businesses (those that already have technology) and these LEGACY businesses either have data breath or data depth BUT NOT BOTH; (IS THIS WHERE THE GREATEST VALUE CAN BE INNOVATED?)
  • NEED to provide ACTIONABLE as well as PHENOTYPIC/GENOTYPIC DATA
  • data depth more important in clinical setting as it drives solutions and cost effective interventions.  For example Foundation Medicine, who supplies genotypic/phenotypic data for patient samples supplies high data depth
  • technologies are moving to data support
  • evidence will need to be tied to umbrella value propositions
  • Informatic solutions will have to prove outcome benefit

 

 

 

 

 

How will Machine Learning be involved in the healthcare value chain?

  • increased emphasis on real time datasets – CONSTANT UPDATES NEED TO OCCUR. THIS IS NOT HAPPENING BUT VALUED BY MANY PLAYERS IN THIS SPACE
  • Interoperability of DATABASES Important!  Many Players in this space don’t understand the complexities integrating these datasets

Other Articles on this topic of healthcare informatics, value based oncology, and healthcare IT on this OPEN ACCESS JOURNAL include:

Centers for Medicare & Medicaid Services announced that the federal healthcare program will cover the costs of cancer gene tests that have been approved by the Food and Drug Administration

Broad Institute launches Merkin Institute for Transformative Technologies in Healthcare

HealthCare focused AI Startups from the 100 Companies Leading the Way in A.I. Globally

Paradoxical Findings in HealthCare Delivery and Outcomes: Economics in MEDICINE – Original Research by Anupam “Bapu” Jena, the Ruth L. Newhouse Associate Professor of Health Care Policy at HMS

Google & Digital Healthcare Technology

Can Blockchain Technology and Artificial Intelligence Cure What Ails Biomedical Research and Healthcare

The Future of Precision Cancer Medicine, Inaugural Symposium, MIT Center for Precision Cancer Medicine, December 13, 2018, 8AM-6PM, 50 Memorial Drive, Cambridge, MA

Live Conference Coverage @Medcity Converge 2018 Philadelphia: Oncology Value Based Care and Patient Management

2016 BioIT World: Track 5 – April 5 – 7, 2016 Bioinformatics Computational Resources and Tools to Turn Big Data into Smart Data

The Need for an Informatics Solution in Translational Medicine

 

 

 

 

Read Full Post »


 

HUBweek 2018, October 8-14, 2018, Greater Boston – “We The Future” – coming together, of breaking down barriers, of convening across disciplinary lines to shape our future

Reporter: Aviva Lev-Ari, PhD, RN

 

HUBweek 2018

Hi Aviva,

 

At HUBweek and in this community, we believe a brighter future is built together. In these times of division, particularly when many are feeling excluded from the benefits brought forth by rapid technological development, there is critical importance in the act of coming together, of breaking down barriers, of convening across disciplinary lines to shape our future.

That’s why this year’s theme for HUBweek is We the Future. It is a call to action and an invitation. Throughout the week, we’ll bring together innovators, artists, and curious minds to explore the ways in which we can shape a more inclusive and equitable future for all.

Today, HUBweek kicks off with dozens of events taking place across the city–from public art tours, a drone zoo, and discussions on nuclear weapons and the impact of emerging technologies on people with disabilities, to a policy hackathon hosted by MIT and the first ever Change Maker Conference.

There are 225+ more experiences to take part in throughout HUBweek–a three-day Forum and a documentary film festival; open dialogues with leading thinkers; a robot block party; and collaborative and participatory art. And we’ve got a little fun in store for you, too–make sure you sign up and stop by The HUB later this week to check it all out.

At its core, HUBweek is a collaboration. If not for our partners and the unwavering support of this community, this would not be a reality. A big thank you to our presenting partners Blue Cross Blue Shield of Massachusetts, Liberty Mutual Insurance, and Merck KGaA, to our sponsors, and to the hundreds of collaborating organizations, speakers, artists, and creative minds that are behind this year’s festival.

On behalf of the HUBweek team and our founders The Boston Globe, Harvard University, Mass. General Hospital, and MIT, we’re thrilled to invite you to join us at HUBweek 2018.

 

Linda Pizzuti Henry

SOURCE

 

From: Linda Pizzuti Henry <hello@hubweek.org>

Reply-To: <hello@hubweek.org>

Date: Monday, October 8, 2018 at 9:38 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Welcome to HUBweek

Read Full Post »


 

Live Coverage: MedCity Converge 2018 Philadelphia: AI in Cancer and Keynote Address

Reporter: Stephen J. Williams, PhD

8:30 AM -9:15

Practical Applications of AI in Cancer

We are far from machine learning dictating clinical decision making, but AI has important niche applications in oncology. Hear from a panel of innovative startups and established life science players about how machine learning and AI can transform different aspects in healthcare, be it in patient recruitment, data analysis, drug discovery or care delivery.

Moderator: Ayan Bhattacharya, Advanced Analytics Specialist Leader, Deloitte Consulting LLP
Speakers:
Wout Brusselaers, CEO and Co-Founder, Deep 6 AI @woutbrusselaers ‏
Tufia Haddad, M.D., Chair of Breast Medical Oncology and Department of Oncology Chair of IT, Mayo Clinic
Carla Leibowitz, Head of Corporate Development, Arterys @carlaleibowitz
John Quackenbush, Ph.D., Professor and Director of the Center for Cancer Computational Biology, Dana-Farber Cancer Institute

Ayan: working at IBM and Thompon Rueters with structured datasets and having gone through his own cancer battle, he is now working in healthcare AI which has an unstructured dataset(s)

Carla: collecting medical images over the world, mainly tumor and calculating tumor volumetrics

Tufia: drug resistant breast cancer clinician but interested in AI and healthcareIT at Mayo

John: taking large scale datasets but a machine learning skeptic

moderator: how has imaging evolved?

Carla: ten times images but not ten times radiologists so stressed field needs help with image analysis; they have seen measuring lung tumor volumetrics as a therapeutic diagnostic has worked

moderator: how has AI affected patient recruitment?

Tufia: majority of patients are receiving great care but AI can offer profiles and determine which patients can benefit from tertiary care;

John: 1980 paper on no free lunch theorem; great enthusiasm about optimization algortihisms fell short in application; can extract great information from e.g. images

moderator: how is AI for healthcare delivery working at mayo?

Tufia: for every hour with patient two hours of data mining. for care delivery hope to use the systems to leverage the cognitive systems to do the data mining

John: problem with irreproducible research which makes a poor dataset:  also these care packages are based on population data not personalized datasets; challenges to AI is moving correlation to causation

Carla: algorithisms from on healthcare network is not good enough, Google tried and it failed

John: curation very important; good annotation is needed; needed to go in and develop, with curators, a systematic way to curate medial records; need standardization and reproducibility; applications in radiometrics can be different based on different data collection machines; developed a machine learning model site where investigators can compare models on a hub; also need to communicate with patients on healthcare information and quality information

Ayan: Australia and Canada has done the most concerning AI and lifescience, healthcare space; AI in most cases is cognitive learning: really two types of companies 1) the Microsofts, Googles, and 2) the startups that may be more pure AI

 

Final Notes: We are at a point where collecting massive amounts of healthcare related data is simple, rapid, and shareable.  However challenges exist in quality of datasets, proper curation and annotation, need for collaboration across all healthcare stakeholders including patients, and dissemination of useful and accurate information

 

9:15 AM–9:45 AM

Opening Keynote: Dr. Joshua Brody, Medical Oncologist, Mount Sinai Health System

The Promise and Hype of Immunotherapy

Immunotherapy is revolutionizing oncology care across various types of cancers, but it is also necessary to sort the hype from the reality. In his keynote, Dr. Brody will delve into the history of this new therapy mode and how it has transformed the treatment of lymphoma and other diseases. He will address the hype surrounding it, why so many still don’t respond to the treatment regimen and chart the way forward—one that can lead to more elegant immunotherapy combination paths and better outcomes for patients.

Speaker:
Joshua Brody, M.D., Assistant Professor, Mount Sinai School of Medicine @joshuabrodyMD

Director Lymphoma therapy at Mt. Sinai

  • lymphoma a cancer with high PD-L1 expression
  • hodgkin’s lymphoma best responder to PD1 therapy (nivolumab) but hepatic adverse effects
  • CAR-T (chimeric BCR and TCR); a long process which includes apheresis, selection CD3/CD28 cells; viral transfection of the chimeric; purification
  • complete remissions of B cell lymphomas (NCI trial) and long term remissions past 18 months
  • side effects like cytokine release (has been controlled); encephalopathy (he uses a hand writing test to see progression of adverse effect)

Vaccines

  •  teaching the immune cells as PD1 inhibition exhausting T cells so a vaccine boost could be an adjuvant to PD1 or checkpoint therapy
  • using Flt3L primed in-situ vaccine (using a Toll like receptor agonist can recruit the dendritic cells to the tumor and then activation of T cell response);  therefore vaccine does not need to be produced ex vivo; months after the vaccine the tumor still in remission
  • versus rituximab, which can target many healthy B cells this in-situ vaccine strategy is very specific for the tumorigenic B cells
  • HoWEVER they did see resistant tumor cells which did not overexpress PD-L1 but they did discover a novel checkpoint (cannot be disclosed at this point)

 

 

 

 

 

 

 

 

 

Please follow on Twitter using the following #hashtags and @pharma_BI

#MCConverge

#AI

#cancertreatment

#immunotherapy

#healthIT

#innovation

#precisionmedicine

#healthcaremodels

#personalizedmedicine

#healthcaredata

And at the following handles:

@pharma_BI

@medcitynews

 

Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal

LIVE – Real Time – 16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 9AM – 5PM, Kresge Auditorium, MIT

Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018

BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center

https://pharmaceuticalintelligence.com/press-coverage/

Read Full Post »

Older Posts »